Evolus Inc.宣布,其产品Evolysse Sculpt在临床试验中成功达到非劣效性的主要终点,同时在统计学上表现出相较于Restylane-Lyft的显著优效性。
Evolus Inc.宣布,其产品Evolysse Sculpt在临床试验中成功达到非劣效性的主要终点,同时在统计学上表现出相较于Restylane-Lyft的显著优效性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.